Today: 9 April 2026
Subscribe
Browse Category

Biotechnology 21 December 2025 - 30 December 2025

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio shares jumped 6.7% Monday, closing at $165.29 after trading as high as $169.75, with volume topping 309,000 shares. The move follows Dec. 1 trial results showing its oral drug tinlarebant met the main goal in Stargardt disease, and a $154-per-ADS public offering. No new company news has emerged since then. Traders are watching if gains hold as the stock trades above its recent offering price.
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma shares plunged 87.65% to $0.29 after late-stage trials of setrusumab failed to meet the main fracture-rate goal in osteogenesis imperfecta. Both Phase 3 studies missed the primary endpoint, though bone mineral density improved and no new safety issues appeared. Analysts cut ratings as the company moved to reduce spending. Trading volume reached about 241 million shares.
30 December 2025
··
Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience (RGC) shares fell 13.98% to $21.16 Friday, closing near session lows after volatile trading and thin volume. The stock’s 52-week range stands at $0.09 to $83.60. RGC’s market cap ended the day near $10.46 billion. Broader U.S. indexes slipped Friday but gained over 1% for the week.
28 December 2025
···
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna shares fell 4.73% to $31.20 Friday, closing out a volatile holiday week with no major company news or FDA headlines in the past 48 hours. After-hours trading edged lower near $31.10. Barron’s and MarketBeat flagged the stock’s sharp move and heavy trading volume. Analyst commentary focused on technicals and sector positioning rather than new fundamentals.
28 December 2025
··
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics shares closed Friday at $55.08, down 2.87% in thin post-holiday trading. ARK Invest disclosed a purchase of 23,170 CRSP shares Friday, valued at about $1.31 million across its ARKK and ARKG ETFs. The broader market ended the session nearly flat, with major indexes little changed ahead of the new year.
27 December 2025
··
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab shares were indicated around $18.58 premarket Friday, valuing the company near $2.1 billion. China approved COBENFY for schizophrenia on December 23, adding to recent company catalysts. U.S. markets reopen for a full session after the Christmas holiday, with thin liquidity and wider spreads expected. ZLAB’s 52-week range spans $16.82 to $44.34, with momentum indicators near oversold levels.
26 December 2025
···
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics shares closed at $27.38 on December 24, up 26% after the company reported a favorable interim safety update for its EDG-7500 therapy in hypertrophic cardiomyopathy. Pre-market trading showed the stock at $27.46 as of 8:52 a.m. ET Friday. No clinically meaningful drops in ejection fraction or new atrial fibrillation were seen in the latest trial cohort. Regular U.S. trading resumes at 9:30 a.m. ET.
26 December 2025
···
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly shares closed up 0.50% at $1,076.98 in light Christmas Eve trading, then slipped to $1,071.74 after hours amid thin volume. The move followed news that U.S. regulators plan to expand Medicaid and Medicare coverage for GLP‑1 obesity drugs, including Lilly’s Zepbound, with a $50 monthly cap for Medicare starting January 2027.
24 December 2025
···
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences shares traded around $18.1–$18.5 on December 24, 2025, holding gains after positive WVE-007 obesity data and a recent capital raise. No new company news crossed the wire, but analysts raised fair value targets following the Phase 1 results showing reduced visceral fat and increased lean mass. At least one after-hours trade printed below the regular close amid thin holiday volume.
24 December 2025
··
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings (RGC) surged 14% to $25.25 on Dec. 24, 2025, despite remaining a pre-revenue company. The move followed a ValueWalk article highlighting RGC’s 17,000% gain in 2025, driven by low float, momentum trading, and a recent 38-for-1 stock split. Intraday prices ranged from $22.00 to $26.33. RGC’s market cap neared $11 billion.
24 December 2025
··
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics announced a $6 million preferred-stock financing with investor David Lazar, who will become chairman and co-CEO. The deal could add up to 111 million common shares if converted, pending shareholder approval. Shares jumped over 60% after hours on December 23, 2025, following the news, after closing at $1.95 in regular trading. Two directors resigned as part of the boardroom changes.
24 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna shares fell 7.48% to $32.29 on Dec. 23 after a sharp rally earlier in the week. The drop followed news of up to $54.3 million in CEPI funding for its bird flu vaccine, with a Phase 3 trial set for early 2026. The stock’s volatility contrasted with broader market gains, as investors reacted to recent headlines and year-end trading dynamics.
24 December 2025
··
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open

The FDA approved new denosumab biosimilars referencing Amgen’s Prolia and XGEVA after markets closed Monday. Amgen shares ended the day up 1.2% at $331.39. Fitch upgraded Amgen’s credit rating to BBB+ with a stable outlook. Post-market trading showed little immediate reaction.
23 December 2025
···
Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience shares rose about 5.4% to $34.26 midday Dec. 22, 2025, after new licensing deals and product expansions. The stock remains down roughly 26% year-to-date despite the rally. Recent catalysts include a licensing agreement with Aptamer Group for hot-start PCR and NGS products and continued integration with Element Biosciences’ AVITI system. TWST’s 52-week range spans $23.30 to $55.33.
22 December 2025
··
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion on Dec. 19, paying a 33% premium and adding two rare-disease drugs with $599 million in combined annual sales. The deal, plus an FDA approval for Cytokinetics and new IPO filings, drove biotech stocks higher ahead of the Christmas-shortened trading week. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·····
1 … 5 6 7 8 9 … 16

Stock Market Today

  • Ares Management (ARES) Share Price Drops 37% YTD, Valuation Concerns Raised
    April 8, 2026, 8:05 PM EDT. Ares Management's (ARES) shares have fallen 37% year-to-date despite solid long-term gains, highlighting shifting investor sentiment in alternative asset managers. The stock trades around $104.83, but valuation models suggest a lower intrinsic value of $87.61, implying a 19.7% overvaluation. Metrics like book value ($12.68 per share) and earnings per share ($5.79) underpin this analysis. Ares' high return on equity (27.6%) contrasts with a cost of equity at $1.93, yet excess returns indicate value creation may not justify the current share price. Investors are advised to weigh fee-based revenue models against market risk reassessments. Simply Wall St rates ARES 0/6 on valuation checks, signaling caution amid volatile market conditions.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop